


PHARMACEUTICAL 2019

Kiniksa Pharmaceuticals Ltd. Rank 123 of 371







Kiniksa Pharmaceuticals Ltd. Rank 123 of 371

The relative strengths and weaknesses of Kiniksa Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 291% points. The greatest weakness of Kiniksa Pharmaceuticals Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is -61%, being 270% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	313,750
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	42,554
Liabilities, Non-Current	0
Other Assets	1,859
Other Compr. Net Income	-4.0
Other Expenses	-214
Other Liabilities	144
Other Net Income	4,719
Property and Equipment	6,356
Research and Development	86,597
Revenues	0
Selling, General and Administrative Expense	21,563

Output Variable	Value in 1000 USD
Assets	321,965
Liabilities	42,698
Expenses	107,946
Stockholders Equity	279,267
Net Income	-103,227
Comprehensive Net Income	-103,229
Economic Capital Ratio	-61%

